These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9043531)

  • 21. [Quality of life in patients with essential arterial hypertension. Part II: The effect of clinical factors].
    Klocek M; Kawecka-Jaszcz K
    Przegl Lek; 2003; 60(2):101-6. PubMed ID: 12939856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.
    Stason WB; Weinstein MC
    N Engl J Med; 1977 Mar; 296(13):732-9. PubMed ID: 402577
    [No Abstract]   [Full Text] [Related]  

  • 23. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophy.
    Rosei EA
    Blood Press; 2003; 12(3):183-4. PubMed ID: 12875482
    [No Abstract]   [Full Text] [Related]  

  • 26. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mild arterial hypertension].
    Halawa B
    Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):571-5. PubMed ID: 1488329
    [No Abstract]   [Full Text] [Related]  

  • 29. [Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension].
    Agabiti-Rosei E; Giovannini E; Mancia G; Novo S; Pede S; Rappelli A; Sau F; Trevi G; Verdecchia P
    Cardiologia; 1999 Mar; 44(3):299-312. PubMed ID: 10327733
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of alpha-blockers on cardiac function.
    Antani JA
    J Assoc Physicians India; 1998; Suppl 1():11-4. PubMed ID: 11229103
    [No Abstract]   [Full Text] [Related]  

  • 31. [Recent knowledge on the role of diastolic blood pressure in hypertensive patients on treatment].
    Leonetti G; Cuspidi C
    Recenti Prog Med; 2008 Apr; 99(4):191-9. PubMed ID: 18595632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
    Journath G; Hellénius ML; Petersson U; Theobald H; Nilsson PM;
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Regression of left ventricular hypertrophy in hypertensive patients].
    Bosa Ojeda F; García González M; Domínguez Rodríguez A; Barragán Acea A; Miralles Ibarra JM; Lacalzada Almeida J; de Armas Trujillo D
    Rev Esp Cardiol; 1997; 50 Suppl 4():74-6. PubMed ID: 9411592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.
    J Hypertens; 1999 Feb; 17(2):151-83. PubMed ID: 10067786
    [No Abstract]   [Full Text] [Related]  

  • 36. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study.
    Jónsdóttir LS; Sigfússon N; Gudnason V; Sigvaldason H; Thorgeirsson G
    J Cardiovasc Risk; 2002 Apr; 9(2):67-76. PubMed ID: 12006913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Treating hypertension" or "lowering blood pressure"? Extending the concept.
    Chalmers J
    Blood Press; 2002; 11(2):68-70. PubMed ID: 12035873
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference?
    Nilsson PM; Journath G; Palm K; Viigimaa M
    Blood Press; 2007; 16(5):301-4. PubMed ID: 17934917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hypertension management in general practice in Iceland].
    Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G
    Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High blood pressure treatment in the elderly.
    Applegate WB
    Clin Geriatr Med; 1992 Feb; 8(1):103-17. PubMed ID: 1576569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.